Lisa Henderson

Highlights from the annual SCOPE conference held in Orlando, FL.

Len Rosenberg, head of clinical operations at Beat AML, discusses the outcome of his company's study, which was four years in the making.

Hope Meely, chief clinical officer at Slope, provides a brief summary of her SCOPE presentation revolving around biospecimen collection.

Hope Meely, chief clinical officer at Slope, discusses the feedback she received following her SCOPE presentation around biospecimen collection.

Hope Meely, chief clinical officer at Slope, offers a look into what she believes is the most important clinical trial development over the past five years.

Hope Meely, chief clinical officer at Slope, dives into what she envisions the clinical trial sector to develop in 2023.

Len Rosenberg, head of clinical operations at Beat AML, reflects on the issues that come with finding patients durable treatment plans.

Len Rosenberg, head of clinical operations at Beat AML, reveals how changing the backbone treatment to a different regimen is beneficial to the patient, in terms of the safety with the same efficacy.

Len Rosenberg, head of clinical operations at Beat AML, comments on how factors, such as proper data collection and reporting techniques, can prove to be efficient and help save lives.

Len Rosenberg, head of clinical operations at Beat AML, comments on how his company not helps to advance the sector, but integrates new ways to conduct clinical trials.

Dr. Sean Bohen, CEO of Olema Oncology, discusses his career and significant contributions to the clinical research and development of numerous oncology drugs that received regulatory approval for various indications. Plus a look at Olema, how they operate, and challenges they face.

Dr. Harsha Rajasimha, Founder and Chairman of IndoUSrare, discusses the emotional reason behind founding the non-profit, programs they offer that are helping rare disease parents/patients, rare disease research in India, and much more.

Dan Brenner, Founder and CEO of 1nHealth, discusses his path into clinical research and patient recruitment, the Gold Eagle Next Generation Board, what millennials/next generations want from organizations they buy from or invest in, how industry can best harness patient data to accurately predict recruitment timelines, and much more.

In this podcast, Dr. Milligan makes the case for studying drugs in pregnant and lactating women on an ongoing basis to understand long-term efficacy and safety, as well as effects of concomitant medications on these women. Sandy believes that the entire ecosystem--regulators, policymakers, governments, physicians, healthcare systems, and industry, need to have a conversation around improving the under-met and unmet needs of women, which includes understanding the unique experiences of women with conditions such as pre-term labor, menopause or endometriosis.

Industry straddling two worlds as new year approaches.

Jane Myles, Vice President, Clinical Trial Innovation at Curebase, discusses her current role, what led her there, and challenges their clients face with DCTs.

Chief Science Officer at Unlearn.AI, Dave Miller, discusses digital twins, their pros and cons for the industry, and developments in Bayesian design and adaptive trials for CDER and CBER.

Industry experts reinforce not putting all eyes on the patient.

Susan Wood, president and CEO of VIDA Diagnostics, discusses her journey into healthcare from an engineering path, changes in the field of imaging, virtual control arms, and much more

Todd Luckritz, Associate Director, Patient Solutions at Myonex, recently left Mayo Clinic as the lead pharmacist for its clinical research programs. In this podcast, Luckritz discusses his journey “bringing protocols to life,” the joy of interacting with patients, and the frustrations with sourcing that led him to make a difference at Myonex.

Cell and gene therapy space set to advance amid recent therapeutic innovation.

Paula Brown Stafford, CEO of Novan, came to her role via increasing clinical development role responsibilities with Quintiles, now IQVIA. In this podcast, she reflects on her professional experiences, her achievements and her advice for clinical trials professionals.

Dr. Shalaan Beg, VP of Oncology for Science 37, discusses his approach to reducing the time to trial activation at an NCI designated cancer center, how to ensure a diverse representation in clinical trials, and his opinion on decentralized and hybrid trials.

Industry making moves towards better utilizing clinical research as a care option.

Christine McSherry, CEO of Casimir and Mindy Leffler, President and Chairman of Casimir, now a part of CRO Emmes, discuss their path to true patient focused drug development based on their experiences raising sons with Duchenne Muscular Dystrophy (DMD). By understanding early and actual measurable endpoints that matter to DMD patients and caregivers, and providing PROs that can capture data that matters, the women hope to influence other diseases and the quality of life for people that have very little time to waste.

Dr. Ian Smith MBE MB ChB.B MedSc(Hons), Founder, Director and Chief Medical Officer of Panthera Biopartners, and Chris Dodd, the company's Chief Commercial Officer, discuss the evolution of the Site Management Organization and Panthera Biopartners, how clinical trials remain mired in underperformance and difficulties, and hybrid trial advancements.

A look into the evolving Applied Clinical Trials podcast.

Praduman “PJ” Jain, CEO & Founder, Vibrent Health; Principal Investigator, NIH All of Us Research Program, Participant Technology Systems Center; Principal Investigator, NIH RADx Program, discusses his involvement in the NIH All of Us program, digital health research tools, and more.

Otis Johnson, PhD, Vice President, Product Line Executive; Chief Diversity, Inclusion and Sustainability Officer, at Clario discusses key changes in the industry that have had the greatest impact, Clario’s first ESG report, and how DE&I initiatives will evolve.

Catharine Grimes, Senior Director, Bristol Myers Squibb Foundation, discusses the goal to increase diversity in clinical trials through the BMS Foundation Diversity in Clinical Trials Career Development Award Program, the Foundation's Global Cancer Disparities Initiative, and more.